Table 1

Patient characteristics

ParameterIM 400 mgIM 800 mgSecond TKIP
No. of patients treated73208154
Median age, y (range)48 (15-78)48 (17-84)47 (18-85).48
Prior cytoreduction, %51 (73)95 (46)60 (39).0001
Splenomegaly, %16 (22)59 (28)41 (27).56
Hemoglobin, g/dL, < 12.0, no. (%)27 (37)82 (39)71 (46).32
WBCs, × 109/L, ≥ 10, no. (%)55 (75)178 (86)112 (73).01
Platelets, × 109/L, > 450, no. (%)22 (30)68 (33)43 (28).62
Peripheral blast, %, any, no. (%)18 (25)76 (36)43 (28).09
Peripheral basophils, %, ≥ 5, no. (%)15 (21)60 (29)39 (25).43
Marrow blast, %, ≥ 5, no. (%)3 (4)18 (9)9 (6).40
Marrow basophils, %, ≥ 5, no. (%)7 (10)32 (15)13 (8).11
Sokal risk, no. (%)
    Low50 (68)132 (63)118 (77).02
    Intermediate22 (30)57 (27)27 (18)
    High1 (2)19 (9)9 (6)
Ph+ > 90%, %67/72 (93)195 (94)133 (86).04
Clonal evolution, %2 (3)7 (3)11/151 (7).15
  • IM indicates imatinib; and WBCs, white blood cells.